OncLive TV

Sara Tolaney, MD, MPH, outlines emerging treatments and trials in the first-line setting for triple-negative breast cancer

Tracy George, MD, discusses the findings from the SUMMIT trial and what they mean for patients with non-advanced systemic mastocytosis.

Mohamed Abdelbaki, MD, discusses second-line targeted therapy options for pediatric low-grade glioma.

Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib as a targeted therapy for relapsed/refractory, NPM1-mutant AML.

Peter Forsberg, MD, discusses the importance of data from the MajesTEC-3 trial in mulitple myeloma, in addition to the next steps for the coMMit Consortium.

Shailee S. Shah, MD, details current screening and diagnostic guidelines for small cell lung cancer–associated LEMS.

Anand Patel, MD, shares primary efficacy results from a phase 2 study evaluating a TKI plus inotuzumab ozogamicin–based therapy in newly diagnosed Ph-positive ALL.

Erica Mayer, MD, MPH, discusses giredestrant plus everolimus vs physician’s choice of endocrine therapy plus everolimus in ER+, HER2-negative locally advanced or metastatic breast cancer.

Pasi A. Jänne, MD, PhD, discusses considerations for selecting a frontline combination regimen in EGFR-mutated NSCLC.

Antonio Gonzalez-Martin, MD, discusses the key safety findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Kevin Punie, MD, discusses PRO data from the phase 3 ASCENT-03 trial.

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.

Samer Alkassis, MD, PhD, discusses how cathepsin protease expression may correlate with survival outcomes to trastuzumab deruxtecan in metastatic breast cancer.

Erika P. Hamilton, MD, discusses data from HER2CLIMB-05 evaluating tucatinib plus trastuzumab/pertuzumab first-line maintenance in HER2-positive breast cancer.

Sara Tolaney, MD, MPH, discusses the clinical implications of sacituzumab govitecan in the first-line treatment of advanced triple-negative breast cancer.

Sara M. Tolaney, MD, MPH, discusses the design and potential significance of the ongoing ELEGANT trial of elacestrant in ER-positive early breast cancer.

Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.

David Rimm, MD, PhD, discusses key conceptual considerations and discrepancies regarding the mechanisms of action of ADCs in breast cancer treatment.

Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Anne Vincent-Salomon, PR, MD, PhD, HDR, highlights persistent gaps that continue to challenge reproducibility and clinical interpretation in the diagnostic classification of invasive lobular carcinoma.

Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.

Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.

Stephen J. Freedland, MD, discusses future avenues for research with enzalutamide in biochemically recurrent prostate cancer.

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

Lorraine Scanlon, MD, discusses IVC tumor thrombus in RCC, its management, and how relieving venous congestion may improve renal function and guide future care.

Roger Li, MD, discusses progression risk in low-grade NMIBC and how AI-based pathology tools may improve identification of patients at risk for high-grade disease.